Skip to main content

Table 2 BMD changes (g/cm2) in different parts before and after treatment

From: Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients

Area

Time

Treatment 1

p*

Treatment 2

p*

Control

p*

Lumbar1

A.1.1.1.1.1.5. 0 M

0.45 ± 0.25

0.49 ± 0.23

0.50 ± 0.18

A.1.1.1.1.1.6. 6 M

0.50 ± 0.16

0.785

0.48 ± 0.22

0.983

0.52 ± 0.27

0.962

A.1.1.1.1.1.7. 12 M

0.54 ± 0.19*

0.045

0.55 ± 0.23

0.680

0.55 ± 0.28

0.785

Lumbar2

A.1.1.1.1.1.8. 0 M

0.65 ± 0.17

0.61 ± 0.12

0.64 ± 0.16

A.1.1.1.1.1.9. 6 M

0.78 ± 0.22*

0.041

0.66 ± 0.13

0.582

0.64 ± 0.17

0.992

A.1.1.1.1.1.10. 12 M

0.72 ± 0.17*

0.049

0.67 ± 0.14

0.460

0.63 ± 0.14

0.980

 

A.1.1.1.1.1.11. 0 M

0.69 ± 0.22

0.62 ± 0.24

0.70 ± 0.21

Lumbar3

A.1.1.1.1.1.12. 6 M

0.72 ± 0.13

0.914

0.69 ± 0.29

0.582

0.73 ± 0.16

0.914

 

A.1.1.1.1.1.13. 12 M

0.81 ± 0.17*

0.024

0.77 ± 0.25*

0.019

0.64 ± 0.27

0.699

 

A.1.1.1.1.1.14. 0 M

0.69 ± 0.18

0.65 ± 0.18

0.66 ± 0.16

Lumbar4

A.1.1.1.1.1.15. 6 M

0.74 ± 0.22

0.664

0.67 ± 0.15

0.929

0.65 ± 0.17

0.983

 

A.1.1.1.1.1.16. 12 M

0.90 ± 0.21*

0.011

0.68 ± 0.14

0.848

0.63 ± 0.14

0.862

 

A.1.1.1.1.1.17. 0 M

0.54 ± 0.17

0.57 ± 0.14

0.57 ± 0.19

Ward area

A.1.1.1.1.1.18. 6 M

0.66 ± 0.14

0.076

0.54 ± 0.19

0.832

0.54 ± 0.14

0.848

 

A.1.1.1.1.1.19. 12 M

0.80 ± 0.17*

0.012

0.67 ± 0.17*

0.036

0.50 ± 0.16

0.411

Femoral neck

A.1.1.1.1.1.20. 0 M

0.68 ± 0.13

0.63 ± 0.14

0.62 ± 0.20

A.1.1.1.1.1.21. 6 M

0.84 ± 0.15*

0.014

0.65 ± 0.17

0.926

0.65 ± 0.17

0.855

A.1.1.1.1.1.22. 12 M

0.80 ± 0.21*

0.047

0.69 ± 0.17*

0.502

0.60 ± 0.17

0.933

  1. Note: *p values indicate the comparison with that before treatment within the same group; indicates p < 0.05 for the comparison between two groups at the same time point on their difference over the treatment